New combination therapy looks promising against ulcer bacteria

October 26, 2009

Results of a new study reveal that a seven-day course of LOAD therapy is superior to LAC at eliminating the H. pylori bacterium in patients with gastritis and peptic ulcers.

Helicobater pylori, a bacteria implicated in and gastritis, was eradicated in 95 percent patients who took a 7-day course of with levofloxacin, , nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.

Results of a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology reveal LOAD therapy is superior to LAC at eliminating the bacterium in patients with gastritis and peptic ulcers. Moreover, Dr. Patrick Basu and his colleagues at Columbia University College of Physicians and Surgeons found that a shorter course of the four-drug combination, seven days vs. a ten-day treatment, is equally effective.

The study included 135 patients with treatment naďve Helicobacter pylori infection who were randomized to LOAD (7 or 10 days) vs. LAC (10 days). There was a total wash out period of six weeks from any prior antibiotic and PPI use prior to the initiation of therapy.

"H. pylori gastritis is a global threat for gastric carcinoma and many therapies have been explored to eradicate this infection with variable success rates," explained Dr. Basu. "Our study demonstrates the therapeutic superiority of LOAD therapy over LAC therapy in a treatment naďve population of patients with H. pylori."

Source: American College of Gastroenterology

Related Stories

Recommended for you

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.